Your browser doesn't support javascript.
loading
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
Carhart-Harris, R L; Bolstridge, M; Day, C M J; Rucker, J; Watts, R; Erritzoe, D E; Kaelen, M; Giribaldi, B; Bloomfield, M; Pilling, S; Rickard, J A; Forbes, B; Feilding, A; Taylor, D; Curran, H V; Nutt, D J.
Afiliación
  • Carhart-Harris RL; Psychedelic Research Group, Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK. r.carhart-harris@imperial.ac.uk.
  • Bolstridge M; Psychedelic Research Group, Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Day CMJ; South London and Maudsley NHS Foundation Trust, London, UK.
  • Rucker J; Psychedelic Research Group, Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Watts R; South London and Maudsley NHS Foundation Trust, London, UK.
  • Erritzoe DE; Psychedelic Research Group, Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Kaelen M; The Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Giribaldi B; South West London and St George's Mental Health NHS Trust, London, UK.
  • Bloomfield M; Psychedelic Research Group, Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Pilling S; Psychedelic Research Group, Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Rickard JA; Psychedelic Research Group, Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Forbes B; Psychedelic Research Group, Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
  • Feilding A; Division of Psychiatry, University College London and Clinical Psychopharmacology Unit, University College London, London, UK.
  • Taylor D; Clinical Psychology and Clinical Effectiveness, University College London, London, UK.
  • Curran HV; Barts Health Pharmaceuticals, Barts Health NHS Trust, the Royal London Hospital, London, UK.
  • Nutt DJ; Institute of Pharmaceutical Science, King's College London, London, UK.
Psychopharmacology (Berl) ; 235(2): 399-408, 2018 02.
Article en En | MEDLINE | ID: mdl-29119217
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psilocibina / Trastorno Depresivo Resistente al Tratamiento / Sistemas de Apoyo Psicosocial / Alucinógenos / Antidepresivos Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Psychopharmacology (Berl) Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psilocibina / Trastorno Depresivo Resistente al Tratamiento / Sistemas de Apoyo Psicosocial / Alucinógenos / Antidepresivos Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Psychopharmacology (Berl) Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Alemania